Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glanatec in Fuchs Endothelial Dystrophy
NCT03249337Phase 4Recruiting
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ripasudil in Fuchs endothelial dystrophy (FED). Started Dec 2017; status: recruiting.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT03249337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249337.